Embolic Protection in TAVR - Is it Necessary?
Embolic Protection in TAVR: Is it Necessary? is a non-CME evening webinar discussion, which will focus on education leading to improved patient care and better outcomes..
This activity is designed for surgeons, general surgeons, primary care physicians, interventional cardiologists and clinical cardiologists.
Educational Needs Assessment
The stroke rate in patients who are treated with Transcatheter Aortic Valve Replacement (TAVR) is approximately 3.5%. Various antithrombotic management strategies have been examined, including different combinations of antiplatelet and anticoagulant therapies. Blood thinners, however, have tangible risks including bleeding issues, and many patients are not able to tolerate the medication. Additionally, research continues to demonstrate that more than two-thirds of patients continue to have ischemic brain lesions. A recent European study, CLEAN-TAVI, examined the use of cerebral embolic protection during TAVR (or TAVI) and showed promising results, with patients having fewer brain lesions and other positive neurological outcomes.
This educational program will examine the use of embolic protection in TAVR illuminating the results of the CLEAN-TAVI study as well as the preliminary data from the SENTINEL study, the sister trial in the U.S.
At the end of this program, the attendees will be able to:
- Describe the stroke risk in TAVR patients and the possible causes
- Identify the various treatment options being evaluated